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Abstract
Human immunodeficiency virus (HIV-1) enters target cells by binding its gp120 exterior envelope glycoprotein to CD4 and one of the
chemokine receptors, CCR5 or CXCR4. CD4-induced (CD4i) antibodies bind gp120 more efficiently after CD4 binding and block the
interaction with the chemokine receptor. Examples of CD4i antibodies are limited, and the prototypes of the CD4i antibodies exhibit only
weak neutralizing activity against primary, clinical HIV-1 isolates. Here we report the identification of a novel antibody, E51, that exhibits
CD4-induced binding to gp120 and neutralizes primary HIV-1 more efficiently than the prototypic CD4i antibodies. The E51 antibody
blocks the interaction of gp120–CD4 complexes with CCR5 and binds to a highly conserved, basic gp120 element composed of the
19-strand and surrounding structures. Thus, on primary HIV-1 isolates, this gp120 region, which has been previously implicated in
chemokine receptor binding, is accessible to a subset of CD4i antibodies.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The production of neutralizing antibodies is a major defense
against viral infections (Burton, 2002; Iwasaki and Nozima,
1977; Lehner, 1989; Morris, 2002; Zinkernagel et al., 2001).
Human immunodeficiency virus (HIV-1) establishes persistent
infections and has evolved to minimize the elicitation and
impact of neutralizing antibodies (Kwong et al., 1998, 2002;
Parren et al., 1999; Wei et al., 2003; Wyatt and Sodroski,
1998). In most HIV-1-infected individuals, the majority of the
antibodies elicited are nonneutralizing, even though they are
directed against the viral envelope glycoproteins, the targets for
antibodies with neutralizing capacity. Early-arising neutraliz-
ing antibodies typically exhibit strain specificity and thus
HIV-1 can escape from these antibodies by altering elements in
the envelope glycoproteins (Arendrup et al., 1992; Wei et al.,
2003). Most HIV-1-infected individuals, after a period of
months or years, elicit cross-reactive neutralizing antibodies.
Particularly in subjects with preservation of immune system
function, such as long-term nonprogressors, considerable titers
of broadly neutralizing antibodies can be produced. Although
primary, clinical isolates of HIV-1 are resistant to neutraliza-
tion compared with tissue culture-passaged viruses (Burton et
al., 1994; Moore et al., 1995; Parren et al., 1998a, 1998b,
Sullivan et al., 1995, 1998; Zwick et al., 2001), the more potent
subset of broadly neutralizing antibodies can inhibit infection
of tissue-cultured cells by primary isolates.
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The in vivo role of antibodies in modulating the level of
HIV-1 infection or disease progression is uncertain, but
several reports suggest that passive administration of HIV-
1-neutralizing antibodies can protect against infection or
mitigate the pathologic outcome of infection (Ferrantelli
and Ruprecht, 2002; Gauduin et al., 1997; Hinkula et al.,
1994; Jackson et al., 1988; Jacobson, 1998; Jacobson et al.,
1993; Katinger, 1994; Laal et al., 1994; Mascola et al.,
1997; Morand-Joubert et al., 1997). A major goal in the
quest for an HIV-1 vaccine is the identification of ap-
proaches that efficiently elicit antibodies with broad and
potent neutralizing capacity.
Neutralizing antibodies recognize the HIV-1 envelope
glycoproteins, which consist of the gp120 exterior glyco-
protein and the gp41 transmembrane glycoprotein. Most
neutralizing antibodies recognize the gp120 glycoprotein,
which has surface-exposed variable loops (Javaherian et al.,
1990; Spear et al., 1994) and carbohydrates that are thought
to facilitate resistance to the binding of inhibitory antibodies
(Reitter et al., 1998; Wei et al., 2003). The gp120 glyco-
protein binds the target cell receptors, CD4, and the che-
mokine receptors, CCR5 or CXCR4 (Alkhatib et al., 1996;
Choe et al., 1996; Deng et al., 1996; Dragic et al., 1996;
Kwong et al., 1998; Oberlin et al., 1996; Rizzuto et al.,
1998; Sattentau et al., 1986; Trkola et al., 1996; Wu et al.,
1996). The receptor-binding regions of gp120 are poten-
tially vulnerable to neutralization, as they must be con-
served among HIV-1 strains and must be exposed at some
point during the process of virus entry. Two groups of
neutralizing antibodies directed against conserved gp120
elements are the CD4-binding site (CD4BS) antibodies and
the CD4-induced (CD4i) antibodies (Burton, 2002; Burton
and Montefiori, 1997; Moore and Burton, 1999; Wyatt et
al., 1998). CD4BS antibodies can block gp120 binding to
CD4 and to the chemokine receptors (Raja et al., 2003) and
vary in neutralizing potency from weak to very strong (Ho
et al., 1991; McInerney et al., 1997; Posner et al., 1991,
1992, 1993; Burton et al., 1994; Saphire et al., 2001; Xiang
et al., 2002b). CD4i antibodies block CCR5 or CXCR4
binding by gp120–CD4 complexes (Babcock et al., 2001;
Trkola et al., 1996; Wu et al., 1996). Only a handful of CD4i
antibodies, all of which are derived from HIV-1-infected
humans, have been reported (Sullivan et al., 1998; Thali et
al., 1993; Xiang et al., 2002a). The prototypic CD4i anti-
bodies, of which 17b and 48d represent two examples,
exhibit weak or modest neutralizing potency against pri-
mary HIV-1 isolates (Sullivan et al., 1998; Xiang et al.,
2002a). The variable loops and the conformational flexibil-
ity of gp120 contribute to the resistance of primary HIV-1
isolates to these CD4i antibodies (Sullivan et al., 1998; Cao
et al., 1997; Kwong et al., 2002). Moreover, CD4i antibod-
ies encounter steric restrictions to binding gp120 after cell-
surface CD4 has been engaged by the virus (A.F. Labrijn et
al., submitted for publication). Thus, single-chain sFv or
Fab fragments of CD4i antibodies exhibit greater neutraliz-
ing potency than complete immunoglobulin molecules (A.F.
Labrijn et al., submitted for publication). Thus, although the
gp120 epitope for CD4i antibodies is critical for CCR5 and
CXCR4 binding and is highly conserved (Xiang et al.,
2002a), the ability of antibodies to target this region effi-
ciently is still uncertain.
The low number of CD4i antibodies identified to date
suggested that their elicitation may not be efficient during
most cases of natural HIV-1 infection. This has prompted a
search for these antibodies in individuals that have been
exposed to HIV-1 but who retain relatively intact immune
systems. One such group consists of individuals whose
HIV-1 infection was recognized very early and who re-
ceived highly active antiretroviral therapy (HAART). This
early intervention has been shown to preserve HIV-1-spe-
cific helper T cells and may predispose such individuals to
control virus infection (Allen et al., 2002; Altfeld et al.,
2002; Rosenberg et al., 1999, 2000). Indeed, upon struc-
tured treatment interruptions (STI) (Allen et al., 2002),
some of these individuals appeared to dampen the resur-
gence of viremia in a progressive fashion, suggesting the
development of more effective immunological control fol-
lowing intermittent exposure to viral antigens (Rosenberg et
al., 2000). One individual who was treated early after in-
fection and experienced several STIs was intensively stud-
ied with respect to the generation of antibodies directed
against the HIV-1 envelope glycoproteins (Montefiori et al.,
2003). This individual was found to have a high frequency
of CD4i antibodies among the Env-reactive antibodies (J.
Robinson and E.S. Rosenberg, unpublished observations).
Several of these CD4i antibodies are novel with respect to
their heavy-chain CDR3 primary sequences, which resem-
ble that of the CCR5 N-terminus and are unusually long
(Choe et al., 2003). Moreover, it has been recently shown
that the heavy-chain CDR3 sequences of some of these
antibodies are posttranslationally modified by tyrosine sul-
fation (Choe et al., 2003), as is the CCR5 N-terminus
(Farzan et al., 1999). Thus, antibodies that mimic the CCR5
chemokine receptor are elicited in some HIV-1-infected
individuals. Here we study the envelope glycoprotein bind-
ing and virus neutralization properties of one of these novel,
sulfated CD4i antibodies, E51.
Results
E51 is a CD4-induced antibody
The properties of the E51 antibody were compared with
those of the 17b antibody, which exhibits binding and neu-
tralization activity typical of those of currently character-
ized CD4i antibodies (Xiang et al., 2002a). To test whether
binding of the E51 antibody to HIV-1 gp120 is influenced
by CD4 binding, wild-type soluble gp120 derived from the
YU2 strain was captured on an ELISA plate by the D7324
antibody directed against the gp120 carboxyl-terminus
(Moore et al., 1994). The binding of the prototypic CD4i
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antibody 17b and the E51 antibody was studied in the
absence or presence of sCD4. The binding of both antibod-
ies was increased in the presence of sCD4 (Fig. 1). Thus,
E51 is a CD4i antibody.
E51 blocks gp120 binding to CCR5
CD4i antibodies are able to block the binding of gp120–
sCD4 complexes to the CCR5 or CXCR4 chemokine recep-
tors (Babcock et al., 2001; Trkola et al., 1996; Wu et al.,
1996). Radiolabeled gp120 from the R5 YU2 HIV-1 isolate
was incubated in the presence or absence of sCD4 with
CCR5-expressing cells (Cf2Th-CCR5 cells). After washing,
the bound gp120 was precipitated by a mixture of sera from
HIV-1-infected individuals and analyzed by SDS–PAGE
(Fig. 2). Inclusion of the E51 or 17b antibodies in the assay
resulted in complete inhibition of gp120–sCD4 binding to
CCR5-expressing cells. By contrast, the C11 antibody,
which recognizes a gp120 epitope distant from the chemo-
kine receptor-binding site (Moore et al., 1994), did not
exhibit inhibitory activity in this assay. Thus, E51, similar
to other CD4i antibodies, can block gp120 interaction with
the CCR5 chemokine receptor.
Mapping the E51 epitope on gp120
To gain insight into the gp120 epitope recognized by the
E51 antibody, the ability of the antibody to precipitate a
panel of mutant gp120 derivatives was examined. The mu-
tants consist of variants of the wt protein derived from the
YU2 HIV-1 strain (Rizzuto and Sodroski, 2000; Rizzuto et
al., 1998). The wt protein corresponds to a gp120 glyco-
protein missing the N-terminus and V1/V2 variable loops.
The use of this protein minimizes the potential effects of
V1/V2 loop movement on epitope exposure and allows the
results to be compared with a large preexisting body of data
on mutant binding to CD4, CCR5, and monoclonal antibod-
ies. Table 1 shows the binding of the E51 antibody to the
panel of mutant envelope glycoproteins, relative to that
observed for the wt glycoprotein. The results are com-
pared with previously generated data on the relative binding
of the mutants to sCD4, CCR5, a CD4BS antibody (F105),
and a CD4i antibody (17b) (Rizzuto and Sodroski, 2000;
Rizzuto et al., 1998). The binding of the antibodies to the
mutant glycoproteins was initially assessed in the absence
of sCD4. Under these conditions, changes in several gp120
regions resulted in decreases in E51 binding. These regions
include the bridging sheet and underlying substructures as
well as the adjacent V3 variable loop. Most of the mutants
that were not recognized efficiently by the E51 antibody are
not globally misfolded proteins, as they were recognized by
at least one conformation-dependent ligand. One exception
is the 383 F/S mutant, which is poorly recognized by a
number of diverse conformation-dependent antibodies and
CD4. The location of the gp120 residues in which changes
resulted in decreases in E51 binding in the absence of sCD4
is shown in Fig. 3, right panel (green and red residues). The
gp120 surface implicated by these data overlaps that in-
volved in CCR5 binding (Fig. 3, left panel).
When the relative binding of the E51 antibody to a
mutant glycoprotein was decreased in the absence of sCD4,
the antibody recognition of the mutant in the presence of
sCD4 was assessed (Fig. 4). E51 recognition was restored in
many cases by sCD4 binding to the mutant wt glycopro-
tein. This indicates that the involved gp120 residue is not
absolutely required for E51 binding. Changes, including
complete deletion, of the gp120 V3 loop fall into this cat-
egory (see V3 in Fig. 4). On the other hand, sCD4 binding
did not restore E51 recognition of the mutants that involve
19-strand residues lysine 421 and glutamine 422. As these
mutants retain the ability to bind sCD4 (Table 1), these
results suggest the critical importance of these residues in
E51 recognition. Even in the presence of sCD4, E51 pre-
cipitation of the 420 I/R and 423 I/S mutants, which contain
alterations in the 19 strand, was lower than that of the wt
protein. These results suggest that the E51 antibody mainly
recognizes highly conserved 19-strand residues 420–423,
which have been previously implicated in CCR5 binding
(Rizzuto and Sodroski, 2000; Rizzuto et al., 1998).
Mutual induction of E51 and CD4 binding
Previous studies have suggested that CD4, the chemo-
kine receptors, and CD4i antibodies all recognize a similar
Fig. 2. Inhibition of gp120 binding to CCR5 by the E51 antibody. Radio-
labeled YU2 HIV-1 gp120 glycoprotein was incubated, in either the ab-
sence () or the presence () of sCD4 (8 g/ml), with Cf2Th-CCR5 cells.
The incubation was performed in the absence (no Ab) or presence of the
E51, 17b, or C11 antibodies. The bound gp120 glycoprotein was detected
by lysis of the Cf2Th-CCR5 cells and precipitation with sera that was
pooled from HIV-1-infected individuals.
Fig. 1. CD4 induction of the binding of the E51 antibody to HIV-1 gp120.
The YU2 HIV-1 gp120 glycoprotein was captured on an ELISA plate using
the D7324 antibody, which is directed against the gp120 carboxyl-termi-
nus. The binding of the 17b and E51 antibodies to the captured gp120
glycoprotein was studied in the absence (open circles) or presence (filled
circles) of sCD4 (8 g/ml).
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conformation of the structurally flexible gp120 glycoprotein
(Kwong et al., 1998; Xiang et al., 2002a, 2002b). In one of
these studies (Xiang et al., 2002b), some mutant wt gly-
coproteins bound poorly to either CD4 or a CD4i antibody,
but were recognized more efficiently in the presence of both
CD4 and CD4i antibody. To determine whether this applied
Table 1
Recognition of HIV-1 gp120 Mutants by Ligandsa
gp120 region Envelope protein sCD4 F105 CCR5 17b E51
YU2 wt 1.00 1.00 1.00 1.00 1.00
C1 107 D/R 1.02 1.14 1.02 0.97 1.24
114 Q/L 0.79 0.75 1.22 0.73 1.22
117 K/D 0.74 0.83 0.15 0.64 0.07
121 K/D 0.73 0.99 0.07 0.00 0.03
122 L/S 0.84 1.11 0.98 1.07 1.03
123 T/D 0.99 1.25 0.08 1.06 0.97
C2 197 N/D 1.34 1.11 1.33 0.80 1.52
199 S/L 1.32 1.04 1.50 0.94 1.15
200 V/S 0.91 1.06 0.84 1.05 0.97
201 I/A 0.90 0.81 0.46 0.67 1.77
203 Q/L 0.85 0.93 0.68 0.88 0.07
207 K/D 0.85 0.98 0.00 0.10 0.08
209 S/L 1.11 1.00 1.00 0.85 1.13
210 F/S 0.81 0.74 0.65 0.81 1.06
211 E/K 1.13 1.24 0.73 1.03 1.26
257 T/D 0.00 0.00 0.05 0.80 0.12
V3 295 N/E 0.75 0.79 0.86 0.73 1.05
298 R/G 1.03 1.14 0.10 0.15 0.02
308 N/D 1.10 1.03 0.31 0.89 1.11
311 L/S 1.12 1.03 0.08 1.05 1.48
330 H/A 0.75 0.64 0.22 0.55 1.42
298–329 (V3) 0.80 0.93 0.00 0.00 0.00
C3 370 E/Q 0.00 0.00 0.17 1.04 1.29
372 V/S 1.03 0.44 0.85 1.08 1.35
373 T/D 1.12 1.10 0.48 1.10 0.76
375 S/W 1.74 0.00 0.59 0.90 0.55
377 N/E 0.71 0.60 0.22 0.52 0.85
381 E/R 0.81 0.96 0.07 0.20 0.01
383 F/S 0.00 0.00 0.04 0.02 0.04
386 N/D 1.14 0.97 1.22 0.97 0.63
C4 419 R/D 0.86 0.82 0.19 0.00 0.03
420 I/R 0.59 0.72 0.06 0.00 0.03
421 K/D 0.86 0.00 0.07 0.00 0.03
422 Q/L 0.53 0.55 0.07 0.00 0.05
423 I/S 0.97 1.03 0.61 0.00 0.07
424 I/S 0.25 0.81 0.37 0.48 0.52
426 M/A 0.69 1.11 0.75 0.69 0.83
429 E/R 1.17 0.82 1.54 1.00 0.88
432 K/A 1.00 1.45 0.06 0.92 0.24
434 M/A 0.90 1.04 1.22 0.65 0.12
435 Y/S 0.33 1.00 0.21 0.00 0.09
436 A/S 1.05 1.23 0.98 0.91 0.36
437 P/A 0.80 0.82 1.79 0.68 0.52
438 P/A 1.18 1.18 0.06 1.00 0.23
439 I/A 0.68 0.84 0.45 0.76 0.69
440 R/D 1.03 1.13 0.09 1.05 0.59
441 G/V 0.67 0.78 0.00 0.70 0.47
442 Q/L 1.11 0.83 2.00 0.74 0.63
444 R/D 0.79 0.74 0.25 0.67 0.68
C5 474D/R 0.59 0.00 1.03 0.81 0.49
a The residue number of the mutants is based on the sequence of the prototype strain HXBc2 (Korber et al., 1998). The value for ligand binding was
determined by immunoprecipitation of radiolabeled protein with a mixture of sera from HIV-1-infected individuals and with specific antibodies/ligands, and
quantified by a PhosphorImager. The values were normalized by the following formula: (mutant protein/wt protein)ligand  (wt protein/mutant protein)serum mixture.
Values for sCD4, F105, CCR5, and 17b binding are from Rizzuto et al. (1998). E51 binding was increased by incubation with sCD4 for all of the mutants
except those contained in the box.
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to the E51 antibody, three mutant wt glycoproteins previ-
ously shown to exhibit mutual induction of CD4 and CD4i
antibody binding (Xiang et al., 2002a) were incubated with
a CD4-immunoglobulin fusion (CD4-lg) protein, the E51
antibody, or both sCD4 and E51. As a control, the wt and
mutant glycoproteins were precipitated by a mixture of sera
from HIV-1-infected individuals. Fig. 5 shows that the 257
T/D mutant, which alters the hydrophobic internal cavity
(the “Phe 43 cavity”) in the CD4-bound conformation of
gp120 (Kwong et al., 1998), was not recognized well by
either CD4-lg or E51. However, when both ligands were
present, precipitation of the 257 T/D mutant was efficient. A
similar but less dramatic effect was observed with the 383
F/S and 435 Y/S mutants. Because of the minimal surface
Fig. 3. Mapping the E51 epitope on the gp120 surface. The HIV-1 gp120 glycoprotein core in the CD4-bound state (Kwong et al:, 1998) is shown from the
perspective of the target cell. In the left panel, the residues colored red are those in which changes resulted in greater than 75% reduction in CCR5 binding
in the presence of sCD4 (Rizzuto and Sodroski, 2000; Rizzuto et al., 1998). In the right panel, residues in which changes result in greater than 80% reduction
in E51 precipitation in the absence of sCD4 are colored. E51 precipitation was completely or partially restored in the presence of sCD4 for those wt mutants
in which the altered residue is colored green. E51 precipitation was undetectable, even in the presence of sCD4, for those wt mutants in which the altered
residue is colored red.
Fig. 4. Precipitation of HIV-1 gp120 mutants by the E51 antibody. Radiolabeled wt or mutant derivatives were incubated with the E51 antibody in the
absence () or presence () of sCD4 (8 g/ml). The precipitated proteins are shown.
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exposure of threonine 257, phenylalanine 383, and tyrosine
435 in the CD4-bound conformation of gp120 (Kwong et
al., 1998), the effects of the introduced changes in these
residues on the binding of CD4 and E51 probably occur
indirectly, through alterations in gp120 conformation. Thus,
achieving a conformation mutually recognized by both E51
and soluble forms of CD4 is optimal when both ligands are
present. These results support a model in which CD4 and
the E51 antibody recognize a similar gp120 conformation.
The neutralizing activity of the E51 antibody
The neutralizing activity of the E51 antibody was com-
pared with that of the prototypic CD4i antibody 17b. The
neutralizing activity of the 17b antibody is typical of that of
previously described CD4i antibodies (Xiang et al., 2002a).
The neutralization assays were performed according to two
protocols. In the first protocol, viruses and antibodies were
preincubated for 1 h at 37°C before addition of the target
cells (Fig. 6A). The 17b and E51 antibodies both neutralized
the viruses with the envelope glycoproteins of the clade B
laboratory-adapted HXBc2 strain of HIV-1 (Fig. 6A). Both
antibodies also demonstrated some inhibition of infection
by viruses with the envelope glycoproteins of the primary
ADA isolate, also from clade B. Although infection by the
ADA virus could be inhibited by 50% at modest concen-
trations of the antibodies, 90% neutralization was not
achieved even at 50 g/ml of antibody. Viruses with the
envelope glycoproteins of two other primary clade B HIV-1
isolates (89.6 and JR-FL) were neutralized by the E51
antibody but not by the 17b antibody. We also examined the
ability of the 17b and E51 antibodies to neutralize viruses
with envelope glycoproteins derived from the globally prev-
alent phylogenetic clade C (MCGP1.3 and SA32 in Fig.
6A). Both 17b and E51 inhibited infection by these viruses,
with E51 exhibiting greater potency against the SA32 virus.
These results indicate that, for numerous HIV-1 isolates,
E51 exhibits neutralizing activity that is as good as or better
than that of 17b.
It has been previously demonstrated that HIV-1 neutral-
ization by CD4i antibodies is less efficient after the virus
has attached to the cell surface, due to steric limitations on
antibody binding to an envelope glycoprotein–CD4 com-
plex (A.F. Labrijn et al., submitted for publication). To
examine whether the E51 antibody could neutralize HIV-1
under such circumstances, recombinant HIV-1 with the
HXBc2, 89.6, or ADA envelope glycoproteins was incu-
bated with the appropriate target cells at 4°C to allow virus
attachment but not entry. The virus–cell mixtures were then
washed and incubated in the absence or presence of either
17b or E51 antibody at 37°C. Under these conditions, the
E51 antibody was as effective as the 17b antibody in neu-
tralizing viruses with the HXBc2 and ADA envelope gly-
coproteins (Fig. 6B). The E51 antibody was slightly more
effective than the 17b antibody in neutralizing viruses with
the 89.6 envelope glycoproteins under these assay condi-
tions. Neutralization of the viruses with the HXBc2 and
89.6 envelope glycoproteins by the E51 antibody was less
efficient in this assay format, compared with the standard
neutralization assay (compare Figs. 6A and B). Thus, the
neutralizing efficiency of the E51 antibody was influenced
by the prior attachment of the virus to the target cell.
Steric restrictions on neutralization by the CD4i antibod-
ies can be at least partially bypassed by single-chain sFv or
Fab fragments of these antibodies (A.F. Labrijn et al., sub-
mitted for publication). We examined the ability of the 17b
and E51 antibodies, or Fab fragments of these antibodies, to
inhibit infection of viruses with envelope glycoproteins de-
rived from the very neutralization-resistant YU2 HIV-1
isolate. The 17b and E51 antibodies demonstrated little
neutralization of the YU2 virus, at concentrations up to 50
g/ml (Fig. 6C). The 17b and E51 Fab fragments exhibited
greater neutralization of the YU2 virus, compared with the
complete antibodies. This suggests that the E51 antibody is
also subject to steric restrictions that decrease its potential
neutralizing activity against primary HIV-1 isolates.
Discussion
Heretofore, the CD4i antibodies have been identified
only rarely in HIV-1-infected individuals, suggesting that
they may not be efficiently elicited by the viral envelope
glycoproteins (Thali et al., 1993). Moreover, the neutraliz-
ing activity of the prototypic CD4i antibodies against pri-
mary HIV-1 isolates is weak or modest (Xiang et al.,
2002a). Several factors, including the conformational flex-
ibility and variable loop masking of gp120, and steric con-
straints on antibody binding, are thought to contribute to the
poor efficacy and inefficient elicitation of CD4i antibodies.
Thus, despite the conservation of this gp120 epitope, which
reflects its involvement in chemokine receptor binding,
Fig. 5. Mutual induction of gp120 binding by sCD4 and the E51 antibody.
Precipitation of the YU2 HIV-1 wt glycoprotein and mutant derivatives
by soluble forms of CD4 and the E51 antibody, alone or in combination, is
shown. The wt and mutant glycoproteins were also precipitated by a
mixture of sera from HIV-1-infected individuals (Pt. Sera).
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there has been considerable uncertainty about the feasibility
of targeting this region with antibodies. Here, we show that
primary HIV-1 isolates can be neutralized by a CD4i anti-
body, E51, derived from an HIV-1-infected individual un-
dergoing STI (Rosenberg et al., 2000). This setting might be
ideal for the generation of antibodies optimized for binding
the HIV-1 envelope glycoproteins, as antiviral helper T cell
responses are preserved by early intervention and exposure
to viral antigens is considerable. Indeed, a high percentage
of HIV-1 envelope glycoprotein-specific antibodies gener-
ated in some STI patients are CD4i antibodies (J. Robinson
and E.S. Rosenberg, unpublished observations). Many of
these resemble E51 with respect to the possession of long
heavy-chain CDR3 loops that contain acidic and sulfated
tyrosine residues (Choe et al., 2003). The resemblance of
these CDR3 sequences to that of the CCR5 amino-terminus
suggests that these antibodies act as soluble mimics of the
chemokine receptor.
Several of the features of the E51 antibody observed in
this study support its resemblance to the chemokine recep-
Fig. 6. Neutralization of HIV-1 by CD4i antibodies. Recombinant HIV-1 viruses expressing luciferase and containing env deletions were pseudotyped with
HIV-1 envelope glycoproteins from the HXBc2, ADA, JR-FL, 89.6, MCGP1.3, SA32, or YU2 isolates. Neutralization by the 17b antibody (E) or E51
antibody (F) was examined. All assays were conducted in triplicate, and the results shown are typical of those obtained in three independent experiments.
(A) The viruses were incubated with the indicated concentration of antibody for 1 h at 37°C prior to exposure to the appropriate target cells. Luciferase activity
in the target cells was measured as described under Materials and methods and is reported as the percentage of activity relative to that observed in the absence
of antibody. (B) The recombinant viruses were incubated with the target cells at 4°C for 2 h, after which antibodies were added at the indicated concentrations
and the temperature was raised to 37°C. After 48 h, luciferase activity in the target cells was measured. (C) Recombinant viruses with YU2 HIV-1 envelope
glycoproteins were incubated with the indicated concentrations of 17b (open circles) or E51 (filled circles) antibodies (left) or Fab fragments (right) for 1 h
at 37°C. The viruses were then added to target cells and luciferase activity was measured as described under Materials and methods.
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tor. First, E51 binds gp120–CD4 complexes and competes
for CCR5 binding. Second, both E51 and the chemokine
receptors preferentially bind the CD4-bound conformation
of gp120. Third, a 19-strand structure on the gp120 gly-
coprotein is important for binding E51, CCR5, and CXCR4.
The binding of these ligands is also influenced by the
structure of the adjacent V3 loop. Requirements for binding
the conserved gp120 19 structure, which is recessed due to
the adjacent V2 and V3 variable loops, may include long
projections, such as those of the E51 heavy-chain CDR3 or
the surface-exposed N-termini of the CCR5 and CXCR4
chemokine receptors. The sulfation of tyrosine residues in
the gp120-binding regions of these ligands increases the
opportunities for interactions involving longer side chains
and electrostatic bonds (Choe et al., 2003, Farzan et al.,
1999). These adaptations may allow antibodies such as E51
to achieve efficient binding to HIV-1 before virus attach-
ment to the target cell CD4, when steric constraints on
antibody binding minimize the effectiveness of the CD4i
antibodies (A.F. Labrijn et al., submitted for publication).
Our results indicate that the E51 antibody is subject to some
extent to these steric constraints.
The demonstration that the chemokine receptor-binding
region of the viral envelope glycoproteins can serve as a
neutralization target on primary HIV-1 isolates should en-
courage efforts to generate antibodies directed against this
region. An understanding of the mechanisms used by HIV-1
to protect this conserved region from neutralizing antibodies
should assist these efforts.
Materials and methods
Cell lines
293T cells were used for expressing HIV-1 gp120 vari-
ants and for producing recombinant viruses for the study of
virus entry and neutralization. Cf2Th cells expressing CD4
and CCR5 were used to study the entry of viruses with R5
envelope glycoproteins, and Cf2Th cells expressing CD4
and CXCR4 were used to study the entry of viruses with X4
or R5X4 envelope glycoproteins (Mirzabekov et al., 1999).
HIV-1 gp120 mutants
The mutants containing single amino acid substitutions
in the YU2 gp120 wt molecule were made by site-directed
mutagenesis using the Quick-Change method. The gp120
wt protein has deletions of gp120 residues 31–81 in the
N-terminus and 128–194, removing the V1 and V2 variable
loops but retaining the conserved V1/V2 stem. (Numbering
of gp120 amino acid residues is based on the sequence of
the prototypic HXBc2 strain of HIV-1, according to current
convention (Korber et al., 1998; Rizzuto et al., 1998).)
Soluble CD4
Soluble CD4 (sCD4) was produced in Drosophila cells
stably transfected with the pMT-sCD4 vector, which ex-
presses four-domain, human sCD4 with a carboxy-terminal
His6 tag. Cells were resuspended in fresh medium and
induced with 750 M CuSO4. After 7 days, the supernatants
were concentrated 20-fold by using the Millipore Pellicon
Ultrafiltration System and applied to an anion-exchange
chromatography column (SP Sepharose Fast Flow, Amer-
sham Pharmacia Biotech). The sCD4 was then purified by
nickel-affinity chromatography (Ni-NTA Superflow, Qia-
gen), according to the manufacturer’s instructions.
E51 antibody and Fab fragments
The human monoclonal antibody E51 was isolated from
an Epstein–Barr virus-transformed B cell line, which was
established from an HIV-1-infected individual (AC-01) un-
dergoing early STI (Rosenberg et al., 2000). Epstein–Barr
virus transformation of B cells was performed as previously
described (Robinson et al., 1990). The antibody was puri-
fied on Protein A-Sepharose and eluted with 3 M MgCl2 at
room temperature.
Fab fragments of the 17b and E51 antibodies were pro-
duced by papain digestion, as described (Kwong et al.,
1999).
Expression of HIV-1 gp120 variants
293T cells grown to 70% confluency in 100-mm dishes
were transfected with 4 g of the pSVIIIenv plasmid, which
expresses the wt and mutant glycoproteins from the YU2
HIV-1 strain, and 1 g of a plasmid expressing the HIV-1
Tat protein, using the Effectene Transfection Reagent (Qia-
gen). Two days after transfection, the medium was re-
moved; the cells were washed once with 10 ml phosphate-
buffered saline (PBS), and labeling medium (4.5 ml
DMEM, 0.5 ml heat-inactivated, dialyzed FBS, 50 l pen-
icillin-streptomycin solution and 20 l (230 Ci)
[35S]cysteine) was added. The cells were incubated at 37°C
for 18 h and the medium was collected and stored at 4°C
after precipitating the cell debris by centrifugation at 1000
rpm for 10 min.
Immunoprecipitation of gp120 glycoproteins
For precipitation of radiolabeled HIV-1 envelope glyco-
proteins, 100 l medium containing the labeled gp120 gly-
coproteins was mixed with 50 l of 10% Protein A-Sepha-
rose (Pharmacia), 50 l 4% bovine serum albumin, and
either 1 g E51 antibody or 2 l pooled sera from HIV-1-
infected patients. PBS was added to bring the total volume
to 1 ml. The samples were rocked at 4°C overnight or at
room temperature for 1–2 h. The Sepharose beads were then
washed once with 1 ml 0.5 M NaCl in PBS and once with
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1 ml PBS. The beads were mixed with 2 gel loading
buffer and boiled for 3 min. After centrifugation to precip-
itate the beads, the supernatants were loaded on a 10%
SDS–polyacrylamide gel. The gel was enhanced with
Autofluor (National Diagnostic) for 20 min before drying at
80°C for 1.5 h and exposure to X-ray film. The gel was also
used for PhosphorImager (Molecular Dynamics) analysis.
ELISA
The wild-type soluble gp120 glycoprotein of YU2 pro-
duced transiently from 293T cells was used to examine
induction of antibody binding by sCD4. The ELISA plate
was coated with sheep antibody D7324 (Aalto BioReagents,
Dublin, Ireland), which recognizes the gp120 carboxyl-
terminus. The gp120 from the 293T cell supernatants was
captured on the plates. The human monoclonal antibody
E51 or 17b (0.03–3.0 g/ml) was incubated for 1.5 h at
37°C with the ELISA plates in the presence of blocking
buffer (2% w/v non-fat dried milk in PBS and 5% FBS).
The plates were washed with 0.2% Tween in PBS. Bound
HMAb was detected with horseradish peroxidase conju-
gated goat anti-human IgG (Fc-specific) (Sigma). The assay
was developed with TMB peroxidase EIA substrate kit
(Bio-Rad). The reaction was stopped by adding 100 l 180
mM HCl and the plate was read at 450 nm.
HIV-1 neutralization assay
The HIV-1-neutralizing ability of the human monoclonal
antibody E51 was tested using a single-round virus entry
assay (Yang et al., 2001). Recombinant HIV-1 expressing
firefly luciferase was produced by transfection of 293T cells
with the pCMV Gag-Pol packaging construct, the pSVII-
Ienv plasmid expressing the envelope glycoproteins of dif-
ferent HIV-1 strains, and the pHIV-Luc vector. Two days
after transfection, the cell supernatant containing recombi-
nant HIV-1 was harvested and its reverse transcriptase (RT)
activity was determined by measuring incorporation of 3H-
TTP. The recombinant viral stocks were aliquoted and fro-
zen.
The target cells (either Cf2Th cells expressing CD4 and
CCR5 or Cf2Th cells expressing CD4 and CXCR4) were
seeded at a density of 6000 cells/well in a 96-well plate and
cultured overnight at 37°C. About 20,000 reverse transcrip-
tase units of virus were incubated with serial dilutions of
antibody for 1 h at 37°C in a 50 l volume. The target cells
were washed once with PBS and the virus–antibody mixture
was added to the cells for 18 h. The cells were then washed,
and fresh medium was added. The cells were cultured for 2
days, washed once with PBS, and lysed with 30 l lucif-
erase lysis buffer. Luciferase assays were performed using
the EG & G Berthold Microplate Luminometer LB 96V
(Promega).
For some neutralization assays, recombinant viruses
were added to target cells at 4°C for 2 h. Cells were then
washed and incubated with the antibody for 18 h at 37°C in
medium. The cells were again washed, and fresh medium
was added. The cells were cultured for 48 more hours before
the luciferase assays were performed, as described above.
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